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BACKGROUND
Although coronary computed tomographic angiography (CTA) improves diagnos-
tic certainty in the assessment of patients with stable chest pain, its effect on 
5-year clinical outcomes is unknown.
METHODS
In an open-label, multicenter, parallel-group trial, we randomly assigned 4146 
patients with stable chest pain who had been referred to a cardiology clinic for 
evaluation to standard care plus CTA (2073 patients) or to standard care alone 
(2073 patients). Investigations, treatments, and clinical outcomes were assessed 
over 3 to 7 years of follow-up. The primary end point was death from coronary 
heart disease or nonfatal myocardial infarction at 5 years.
RESULTS
The median duration of follow-up was 4.8 years, which yielded 20,254 patient-
years of follow-up. The 5-year rate of the primary end point was lower in the CTA 
group than in the standard-care group (2.3% [48 patients] vs. 3.9% [81 patients]; 
hazard ratio, 0.59; 95% confidence interval [CI], 0.41 to 0.84; P = 0.004). Although 
the rates of invasive coronary angiography and coronary revascularization were 
higher in the CTA group than in the standard-care group in the first few months 
of follow-up, overall rates were similar at 5 years: invasive coronary angiography 
was performed in 491 patients in the CTA group and in 502 patients in the stan-
dard-care group (hazard ratio, 1.00; 95% CI, 0.88 to 1.13), and coronary revascu-
larization was performed in 279 patients in the CTA group and in 267 in the 
standard-care group (hazard ratio, 1.07; 95% CI, 0.91 to 1.27). However, more 
preventive therapies were initiated in patients in the CTA group (odds ratio, 1.40; 
95% CI, 1.19 to 1.65), as were more antianginal therapies (odds ratio, 1.27; 95% 
CI, 1.05 to 1.54). There were no significant between-group differences in the rates 
of cardiovascular or noncardiovascular deaths or deaths from any cause.
CONCLUSIONS
In this trial, the use of CTA in addition to standard care in patients with stable 
chest pain resulted in a significantly lower rate of death from coronary heart dis-
ease or nonfatal myocardial infarction at 5 years than standard care alone, without 
resulting in a significantly higher rate of coronary angiography or coronary revascu-
larization. (Funded by the Scottish Government Chief Scientist Office and others; 
SCOT-HEART ClinicalTrials.gov number, NCT01149590.)
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Patients with stable chest pain sug-gestive of coronary heart disease can be evaluated with a variety of noninvasive 
stress tests that incorporate electrocardiography, 
radionuclide scintigraphy, echocardiography, or 
magnetic resonance imaging.1-6 Over the past 
50 years or more, these techniques have been 
shown to be useful in assisting with the diagno-
sis of coronary heart disease, as well as in pro-
viding important prognostic information. As such, 
they are the focus of current international guide-
lines for the assessment of patients with stable 
chest pain.4-6
Coronary computed tomographic angiography 
(CTA) is increasingly being used to assess pa-
tients with stable chest pain because it has high 
sensitivity and specificity for the detection of 
coronary heart disease.7,8 In the Scottish Com-
puted Tomography of the Heart (SCOT-HEART) 
trial,9 we previously found that among patients 
who had been referred to a cardiology clinic with 
stable chest pain, CTA clarified the diagnosis 
and altered subsequent investigations and treat-
ments.9 Subsequent post hoc analyses showed 
that the use of CTA in addition to standard care 
resulted in better clinical outcomes than stan-
dard care alone.10 The Prospective Multicenter 
Imaging Study for Evaluation of Chest Pain 
(PROMISE) also involved patients with symptoms 
suggestive of coronary heart disease who under-
went further noninvasive testing.11,12 In a head-
to-head comparison of functional testing with 
CTA, no significant difference in clinical out-
comes was observed.
Both the SCOT-HEART and PROMISE trials 
followed patients for a relatively short time (20 
to 22 months), and the longer-term effects on 
coronary heart disease events are unknown. We 
now report the 5-year clinical outcomes of the 
SCOT-HEART trial13 to determine the effect of 
CTA on longer-term investigations, treatments, 
and clinical events.
Me thods
Trial Design and Oversight
This open-label, randomized, controlled, parallel-
group trial was performed at 12 centers across 
Scotland. The trial, which has been described 
previously,9,10,13 was conducted with the approval 
of the South East Scotland Research Ethics 
Committee. The protocol, available with the full 
text of this article at NEJM.org, was designed by 
the grant applicants with input from the trial 
steering committee (see the Supplementary Ap-
pendix, available at NEJM.org).
The funders had no role in the design or 
conduct of the trial or in the collection, analysis, 
or reporting of data. The steering committee 
vouches for the accuracy and completeness of 
the data and the analyses and for the fidelity 
of the trial to the protocol.
Patient Population and Randomization
Patients 18 to 75 years of age who had stable 
chest pain and who had been referred by a pri-
mary care physician to an outpatient cardiology 
clinic were eligible for inclusion.9,10,13 Exclusion 
criteria are listed in the Supplementary Appen-
dix. All participants provided written informed 
consent.
All patients underwent a routine clinical evalu-
ation, including, if deemed appropriate, symptom-
limited exercise electrocardiography. The symp-
toms, diagnosis, further investigations (stress 
imaging or invasive coronary angiography), and 
treatment strategy were documented at the end 
of the clinic visit, before recruitment or random-
ization. Patients were then randomly assigned in 
a 1:1 ratio to standard care plus CTA or to stan-
dard care alone; randomization was performed 
with the use of a Web-based system to ensure 
concealment of group assignment. The random-
ization incorporated the use of minimization 
to balance age, sex, body-mass index, diabetes 
mellitus, history of coronary heart disease, and 
atrial fibrillation.
Subsequent Investigations and Treatments
Management of the patient’s condition in the 
light of all available information was at the dis-
cretion of the attending clinician. Physicians car-
ing for patients in the CTA group were prompted 
to consider the results of the CTA in their man-
agement decisions, and physicians caring for pa-
tients in the standard-care group were prompted 
to consider a prespecified cardiovascular risk 
score (the ASSIGN score, which ranges from 1 to 
99, with higher scores indicating a higher risk of 
cardiovascular disease14) in their management 
decisions (additional details are provided in the 
Supplementary Appendix). Specifically, when 
there was evidence of nonobstructive (10 to 70% 
cross-sectional luminal stenosis) or obstructive 
coronary artery disease on the CTA, or when a 
patient had an ASSIGN score of 20 or higher, the 
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attending clinician and primary care physician 
were prompted by the trial coordinating center 
to prescribe preventive therapies (e.g., aspirin 
and a statin).13
Clinical Follow-up
There were no trial-specific visits, and all follow-
up information was obtained from data collected 
routinely by the Information and Statistics Divi-
sion and the electronic Data Research and In-
novation Service of the National Health Service 
(NHS) Scotland, as described previously.9,10 (Ad-
ditional information is provided in the Supple-
mentary Appendix.) The inpatient and day-case 
national data set contains episode-level data 
from all hospitals in Scotland, for events that 
occurred in Scotland or that occurred outside 
Scotland but resulted in a transfer to a hospital 
in Scotland. These data include diagnostic codes 
from discharge records, which were classified 
according to the International Classification of Dis-
eases, 10th Revision, and procedural codes from the 
Classification of Interventions and Procedures of 
the Office of Population Censuses and Surveys, 
as described previously.9,10,15-17
Clinical End Points
The clinical end points that were assessed in-
cluded death (cardiovascular death, noncardiovas-
cular death, death from coronary heart disease, 
and death from any cause), myocardial infarction, 
and stroke. The primary end point was death 
from coronary heart disease or nonfatal myocar-
dial infarction. There was no formal event adju-
dication, and end points were classified primar-
ily on the basis of diagnostic codes. However, in 
cases of uncertainty, events and causes of death 
were categorized by two of the authors, who were 
unaware of the trial assignments.9
Process-of-Care End Points
Rates of invasive coronary angiography and coro-
nary revascularization (including percutaneous 
coronary intervention and coronary-artery bypass 
grafting) were obtained from records of inpa-
tient and day-case episodes and were cross-
checked by review of individual coronary angio-
grams within the national Picture Archiving and 
Communications Systems.9,10 Documentation of 
patients’ medications was obtained from the 
Scottish National Prescribing Information Sys-
tem of the Information and Statistics Division 
of NHS Scotland (see the Supplementary Ap-
pendix).10
Statistical Analysis
The original primary end point of the trial was 
the proportion of patients who received a diag-
nosis of angina pectoris caused by coronary 
heart disease at 6 weeks.9 However, because we 
acknowledged the potential long-term clinical 
consequences of a change in diagnosis, our pre-
specified primary long-term end point was the 
proportion of patients who died from coronary 
heart disease or had a nonfatal myocardial in-
farction at 5 years.13 On the basis of an esti-
mated 5-year event rate of 13.1%, we hypothe-
sized that the trial would have 80% power to 
detect a rate of the primary long-term end point 
that was 2.8 percentage points lower in the CTA 
group than in the standard-care group. A two-
sided P value of less than 0.05 was considered to 
indicate statistical significance.13
All analyses were performed according to the 
intention-to-treat principle. Missing data were 
removed from the analyses, except for data on 
deaths, which were censored at the time the 
patient was lost from the trial. End points were 
analyzed with the use of Cox regression models, 
adjusted for center and minimization variables, 
and cumulative event curves were constructed. 
We also performed a post hoc 12-month land-
mark analysis, since we reasoned that any 
changes in the use of invasive coronary angiog-
raphy and the incidence of coronary revascular-
ization that were driven by the results of CTA 
should have been observed by this time point.
Data are reported as means and standard 
deviations, medians and interquartile ranges, 
and hazard ratios or odds ratios with 95% con-
fidence intervals, as appropriate. Because there 
was no adjustment for multiplicity in the analy-
sis of secondary end points, results are reported 
as point estimates and 95% confidence intervals. 
The confidence intervals have not been adjusted 
for multiplicity, so intervals should not be used 
to infer definitive treatment effects. All analyses 
were performed with the use of R software, ver-
sion 3.4.3 (R Foundation for Statistical Com-
puting). Anonymized data and R code used in 
the statistical analysis will be made available on 
request.
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R esult s
Trial Participants and Follow-up
From November 2010 through September 2014, 
we recruited 4146 patients with stable chest pain 
at 12 cardiology centers across Scotland (Fig. S1 in 
the Supplementary Appendix). Baseline clinical 
characteristics (Table 1), CTA findings, the influ-
ence of each assigned strategy on diagnostic cer-
tainty, and subsequent initial management have 
been reported previously9,10 (see also Tables S1 
through S3 in the Supplementary Appendix). 
Among patients who remained registered in Scot-
land throughout the trial (4080 patients [98.4%]), 
no patient withdrew consent, and we had com-
plete data over a median of 4.8 years (3 to 7 years 
of follow-up) in both trial groups, comprising 
20,254 patient-years of follow-up through Janu-
ary 31, 2018.
Subsequent Management
During follow-up, patients assigned to CTA were 
more likely than patients assigned to standard 
care alone to have commenced preventive thera-
pies (19.4% [402 patients] vs. 14.7% [305 patients]; 
odds ratio, 1.40; 95% confidence interval [CI], 
1.19 to 1.65) and antianginal therapies (13.2% 
[273 patients] vs. 10.7% [221 patients]; odds ratio, 
1.27; 95% CI, 1.05 to 1.54). The overall differ-
ences in prescribing persisted over 5 years (Table 
S4 in the Supplementary Appendix).
At 5 years, there was no difference between 
the groups in the frequency of invasive coronary 
angiography; the procedure was performed in 
491 patients (23.6%) in the CTA group and in 
502 patients (24.2%) in the standard-care group 
(hazard ratio, 1.00; 95% CI, 0.88 to 1.13) 
(Fig. 1A). Although we had previously seen a 
trend toward a higher rate of early coronary re-
vascularization in the group assigned to CTA,9 
there was no difference in the frequency of coro-
nary revascularization between the groups at 
5 years; this procedure was performed in 279 
patients (13.5%) in the CTA group and in 267 
(12.9%) in the standard-care group (hazard ra-
tio, 1.07; 95% CI, 0.91 to 1.27) (Fig. 1B). Beyond 
the first 12 months, patients assigned to CTA 
had lower rates of invasive coronary angiography 
than patients who received standard care alone 
(hazard ratio, 0.70; 95% CI, 0.52 to 0.95), as well 
as lower rates of coronary revascularization 
(hazard ratio, 0.59; 95% CI, 0.38 to 0.90) (Fig. S2 
in the Supplementary Appendix).
Clinical End Points
The rate of the primary long-term end point 
(death from coronary heart disease or nonfatal 
myocardial infarction) was lower in the CTA 
group than in the standard-care group (2.3% [48 
patients] in the CTA group vs. 3.9% [81 patients] 
in the standard-care group; hazard ratio, 0.59; 
95% CI, 0.41 to 0.84; P = 0.004) (Table 2 and 
Fig. 2). This difference was driven primarily by a 
lower rate of nonfatal myocardial infarction in 
the CTA group than in the standard-care group 
(hazard ratio, 0.60; 95% CI, 0.41 to 0.87). The 
results for the components of the primary end 
point are shown in Table 2.
There was no evidence of heterogeneity of 
effect on the primary end point across a range 
of subgroups (Fig. 3) and trial centers (Fig. S3 in 
the Supplementary Appendix). With the exclusion 
of the first 50 days of follow-up to account for 
the delay in the implementation of treatment on 
the basis of CTA findings,10 landmark analysis 
provided a point estimate for the lower rate of 
the primary end point in the CTA group that was 
similar to that for the overall 5-year analysis 
(hazard ratio, 0.53; 95% CI, 0.36 to 0.78). Among 
the 48 patients assigned to CTA who subse-
quently met the primary end point, 22 patients 
had obstructive disease, 17 had nonobstructive 
disease, 3 had normal coronary arteries on 
their baseline computed tomographic scan, and 
6 did not attend their appointment and therefore 
did not undergo CTA.
Clinical outcomes did not differ between pa-
tients who had possible angina and those who 
had nonanginal chest pain, as defined in the 
National Institute for Health and Care Excellence 
(NICE) guidelines (see the Supplementary Meth-
ods section and Table S5 in the Supplementary 
Appendix).18-20 Although the overall 5-year event 
rates were higher among patients with possible 
angina (3.1%) than among those with nonangi-
nal chest pain (1.8%), the absolute difference in 
the primary end point at 5 years between the 
CTA group and the standard-care group was 
similar in these two patient populations (differ-
ence of 1.5 percentage points in patients with 
possible angina and 1.3 percentage points in 
patients with nonanginal chest pain) (Fig. 3, and 
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Characteristic
All Participants 
(N = 4146)
Standard Care 
(N = 2073)
Standard Care plus CTA 
(N = 2073)
Male sex — no. (%) 2325 (56) 1163 (56) 1162 (56)
Age — yr 57.1±9.7 57.0±9.7 57.1±9.7
Body-mass index† 29.7±5.9 29.8±6.0 29.7±5.8
Cardiovascular risk factor — no./total no. (%)
Current or former smoker 2185/4139 (53) 1090/2068 (53) 1095/2071 (53)
Hypertension 1395/4105 (34) 683/2053 (33) 712/2052 (35)
Diabetes mellitus 444/4146 (11) 221/2073 (11) 223/2073 (11)
Hypercholesterolemia 2176/4142 (53) 1077/2070 (52) 1099/2072 (53)
Family history of CHD 1716/4103 (42) 829/2052 (40) 887/2051 (43)
History of CHD — no./total no. (%) 372/4142 (9) 186/2070 (9) 186/2072 (9)
Atrial fibrillation — no./total no. (%) 84/4142 (2) 42/2070 (2) 42/2072 (2)
Relevant medications — no./total no. (%)
Antiplatelet agent 1993/4142 (48) 984/2070 (48) 1009/2072 (49)
Statin 1786/4142 (43) 884/2070 (43) 902/2072 (44)
Beta-blocker 1357/4142 (33) 672/2070 (32) 685/2072 (33)
ACE inhibitor or ARB 685/4142 (17) 344/2070 (17) 341/2072 (16)
Calcium-channel blocker 377/4142 (9) 194/2070 (9) 183/2072 (9)
Nitrates 1160/4142 (28) 590/2070 (29) 570/2072 (28)
Other antianginal agent 191/4142 (5) 96/2070 (5) 95/2072 (5)
Anginal symptoms — no./total no. (%)‡
Typical angina 1462/4142 (35) 725/2070 (35) 737/2072 (36)
Atypical angina 988/4142 (24) 486/2070 (23) 502/2072 (24)
Nonanginal chest pain 1692/4142 (41) 859/2070 (41) 833/2072 (40)
Resting ECG results — no./total no. (%)
Normal 3492/4100 (85) 1735/2051 (85) 1757/2049 (86)
Abnormal 608/4100 (15) 316/2051 (15) 292/2049 (14)
Stress ECG performed — no./total no. (%) 3517/4128 (85) 1764/2063 (86) 1753/2065 (85)
Normal results 2188/3283 (67) 1103/1651 (67) 1085/1632 (66)
Inconclusive results 566/3283 (17) 284/1651 (17) 282/1632 (17)
Abnormal results§ 529/3283 (16) 264/1651 (16) 265/1632 (16)
Further investigations — no./total no. (%) 1315/4140 (32) 633/2069 (31) 682/2071 (33)
Stress imaging
Radionuclide scintigraphy 389/4142 (9) 176/2070 (9) 213/2072 (10)
Other imaging 30/4142 (<1) 16/2070 (<1) 14/2072 (<1)
Invasive coronary angiography 515/4142 (12) 255/2070 (12) 260/2072 (13)
Diagnosis at baseline — no./total no. (%)
CHD 1938/4142 (47) 982/2070 (47) 956/2072 (46)
Angina due to CHD 1485/4142 (36) 742/2070 (36) 743/2072 (36)
*  Plus–minus values are means ±SD. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, 
CHD coronary heart disease, CTA computed tomographic angiography, and ECG electrocardiography.
†  Body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Anginal symptoms were classified according to the National Institute for Health and Care Excellence (NICE) criteria.18-20
§  The results were categorized as abnormal if they showed evidence of myocardial ischemia.
Table 1. Baseline Characteristics of the Participants before Randomization.*
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Table S5 and Fig. S4 in the Supplementary Ap-
pendix).
Discussion
In our previous report from the SCOT-HEART 
trial, we found that the use of CTA had a signifi-
cant effect on the diagnosis and treatment of 
patients who had been referred for evaluation 
of stable chest pain, in that it influenced both 
the certainty and the frequency of the diagnosis 
of coronary heart disease and led to alterations 
in management.9 Here, we report the 5-year clini-
cal outcomes.13 We found that the use of CTA, 
with consequent changes in treatment, resulted 
in a significantly lower rate of death from coro-
nary heart disease or nonfatal myocardial in-
farction than standard care alone. Although the 
rates of invasive coronary angiography and coro-
nary revascularization were higher in the CTA 
group than in the standard-care group in the 
first few months of follow-up, we did not find 
any differences in the overall use of invasive 
coronary angiography and coronary revascular-
ization at 5 years. Our findings suggest that the 
use of CTA resulted in more correct diagnoses of 
coronary heart disease than standard care alone, 
which, in turn, led to the use of appropriate 
therapies, and this change in management re-
sulted in fewer clinical events in the CTA group 
than in the standard-care group.
In the SCOT-HEART9 and PROMISE11 trials, 
the use of CTA resulted in a higher rate of detec-
tion of obstructive coronary heart disease, as 
confirmed by invasive coronary angiography, than 
standard care alone (SCOT-HEART trial) or func-
tional testing (PROMISE trial). Invasive coronary 
angiography and coronary revascularization are 
more likely to be used appropriately in patients 
who receive a correct diagnosis of coronary heart 
disease9,11; patients who receive a correct diag-
nosis are also more likely to receive appropriate 
preventive therapies10 and may have greater moti-
vation to implement healthy lifestyle modifica-
tions. In addition, the SCOT-HEART trial encour-
aged initiation of secondary prevention strategies 
in patients with nonobstructive coronary artery 
disease. Among patients in the CTA group, ap-
proximately half the subsequent myocardial infarc-
tions occurred among patients who had nonob-
structive disease at baseline. This proportion was 
probably higher among patients who received stan-
dard care alone, since nonobstructive disease may 
have been unrecognized and untreated in some 
of the patients in that group. In the PROMISE 
trial, in which preventive ther apies were not 
mandated, two thirds of subsequent cardiac 
events occurred in patients with nonobstructive 
disease.21 Finally, event rates in the two groups 
in the current trial were similar until diagnoses 
Figure 1. Percentage of Patients Who Underwent Invasive Coronary 
 Angiography and Coronary Revascularization, According to Year of Follow-up.
Patients with stable chest pain were randomly assigned to undergo coronary 
computed tomographic angiography (CTA) in addition to receiving standard 
care or to receive standard care alone. Shown are cumulative event curves 
for the percentage of patients who underwent invasive coronary angiogra-
phy (Panel A) and coronary revascularization (Panel B) over the course of 
the 5-year follow-up.
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were confirmed and alterations in treatment were 
made after approximately 7 weeks,10 which sug-
gests that the groups were similar at baseline 
and changes in outcomes occurred only once 
treatment interventions directed by CTA find-
ings were initiated. We hypothesize that the 
immediate reductions in events were mediated 
through the use of aspirin22,23 and coronary re-
vascularization procedures,24,25 and that longer-
term benefits are attributable to lifestyle modi-
fication26 and statin therapy.27
Previous studies have suggested that the use 
of CTA is associated with higher early rates of 
both invasive coronary angiography and coronary 
revascularization.9,11,28 Over the 5-year follow-up, 
we found that these higher procedure rates were 
no longer apparent. We performed landmark 
analyses at 12 months to distinguish the imme-
diate effects of CTA from the longer-term conse-
quences. We found that beyond 12 months, rates 
of invasive coronary angiography and coronary 
revascularization were higher in the standard-
care group than in the CTA group. This would 
be consistent with both the emergence of unrec-
ognized disease and nonfatal myocardial infarc-
tion in the standard-care group and the reduction 
in disease progression in the CTA group owing to 
the implementation of lifestyle modifications and 
preventive therapies.27
Some observers have highlighted the low car-
diovascular event rates in trials of CTA involv-
ing patients with stable chest pain, which has 
prompted others to suggest that such patients 
should not undergo cardiovascular testing at all. 
In the SCOT-HEART trial, we enrolled patients 
with a broad range of cardiovascular risks. Over-
all, we observed event rates of approximately 4% 
over 5 years, which equates to 8% over 10 years. 
However, half the trial population had normal 
or near-normal coronary arteries, which implies 
End Point
All Participants 
(N = 4146)
Standard Care 
(N = 2073)
Standard Care 
plus CTA 
(N = 2073)
Hazard Ratio 
(95% CI)†
number of patients (percent)
Primary end point: death from CHD or non-
fatal myocardial infarction‡
129 (3.1) 81 (3.9) 48 (2.3) 0.59 (0.41–0.84)§
Secondary end points
Death from CHD, nonfatal myocardial  
infarction, or nonfatal stroke‡
160 (3.9) 97 (4.7) 63 (3.0) 0.65 (0.47–0.89)
Nonfatal myocardial infarction 117 (2.8) 73 (3.5) 44 (2.1) 0.60 (0.41–0.87)
Nonfatal stroke 35 (0.8) 20 (1.0) 15 (0.7) 0.74 (0.38–1.44)
Death
From CHD‡ 13 (0.3) 9 (0.4) 4 (0.2) 0.46 (0.14–1.48)
From any cause 86 (2.1) 43 (2.1) 43 (2.1) 1.02 (0.67–1.55)
Cardiovascular 17 (0.4) 12 (0.6) 5 (0.2) 0.43 (0.15–1.22)
Noncardiovascular 69 (1.7) 31 (1.5) 38 (1.8) 1.24 (0.77–2.00)
Procedures
Invasive coronary angiography 993 (24.0) 502 (24.2) 491 (23.7) 1.00 (0.88–1.13)
Revascularization¶ 546 (13.2) 267 (12.9) 279 (13.5) 1.07 (0.91–1.27)
Percutaneous coronary intervention 431 (10.4) 212 (10.2) 219 (10.6) 1.06 (0.88–1.28)
Coronary-artery bypass grafting 131 (3.2) 62 (3.0) 69 (3.3) 1.12 (0.80–1.58)
*  For the composite end points, data are for the first event only.
†  The hazard ratios were determined with the use of adjusted Cox regression models. The confidence intervals have not 
been adjusted for multiplicity, so intervals should not be used to infer definitive treatment effects.
‡  In all cases of death from CHD, the cause of death was myocardial infarction.
§  P = 0.004 for the comparison between CTA plus standard care and standard care alone.
¶  A total of 12 patients had percutaneous coronary intervention followed by coronary-artery bypass grafting, and 4 patients 
had coronary-artery bypass grafting followed by percutaneous coronary intervention.
Table 2. Primary and Secondary End Points after a Median Follow-up of 4.8 Years.*
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that patients with nonobstructive or obstructive 
coronary heart disease would have 10-year event 
rates of approximately 16%. This highlights the 
importance of promptly and accurately identify-
ing the presence of coronary heart disease.
Strategies to stratify patients before testing 
have been proposed and are included in current 
guidelines.4-6 However, these strategies still lead 
to overtesting, owing to the poor predictive ac-
curacy of the current scoring systems.20,29 Recent-
ly, NICE has recommended a simple symptom-
based approach that would classify patients into 
one of two categories: those with nonanginal 
chest pain and those with possible angina.19 We 
found that patients with possible angina were at 
higher risk than those with nonanginal chest 
pain, especially in the first 3 to 6 months after 
the onset of symptoms, which perhaps reflects 
the fact that patients with recent onset of angina 
pectoris constitute a particularly high-risk 
group.30,31 However, overall, all patients appeared 
to derive similar benefits from CTA, which raises 
the question of whether more widespread testing 
may be helpful, irrespective of symptoms. Our 
data suggest that 63 patients with stable chest 
pain would need to be referred for CTA to pre-
vent 1 fatal or nonfatal myocardial infarction 
over the course of 5 years.
We acknowledge that there are some limita-
tions of the trial. First, this was an open-label 
trial, and ascertainment bias is inherent to the 
trial design. Because event adjudication was not 
blinded and clinical diagnoses were coded with 
knowledge of the assigned trial group, the risk 
of ascertainment bias is probably higher. This 
risk may have been mitigated, however, by the 
fact that the primary long-term end point was 
composed of hard clinical events. Second, we do 
not have data on lifestyle alterations during fol-
low-up and can only speculate that these may 
have been greater in the CTA group than in the 
standard-care group. Third, cardiovascular-risk 
thresholds for the initiation of preventive thera-
pies have fallen since the trial was completed, 
and it is unclear whether the benefits of CTA 
will be maintained with these lower thresholds. 
Finally, the benefit of CTA with respect to the 
rate of death from coronary heart disease and 
nonfatal myocardial infarction (1.6 percentage 
points lower than the rate with standard thera-
py) may be considered modest, but this absolute 
benefit is similar to, if not greater than, the 
benefits achieved in recent pharmaceutical inter-
ventional trials involving patients with estab-
lished coronary heart disease.32-34
In conclusion, in the SCOT-HEART trial, we 
found that the use of CTA in patients who had 
been referred to a cardiology clinic for assess-
ment of stable chest pain resulted in a lower 
subsequent risk of death from coronary heart 
disease or nonfatal myocardial infarction than 
standard care alone. This benefit was achieved 
Figure 2. Cumulative Incidence of Death from Coronary Heart Disease  
or Nonfatal Myocardial Infarction.
Panel A shows cumulative event curves for the primary end point of death 
from coronary heart disease or nonfatal myocardial infarction among pa-
tients assigned to CTA in addition to standard care and those assigned to 
standard care alone. Panel B shows the cumulative risk of nonfatal myocar-
dial infarction in each group. The inset in each panel shows the same data 
on an enlarged y axis.
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without greater long-term use of invasive coro-
nary angiography or coronary revascularization 
in the CTA group.
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